Shilpa Medicare Unit IV, Jadcherla has cleared TGA, Australia GMP inspection
This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The USFDA inspectors issued the observations after a product pre-approval inspection of the biologics facility in Bachupally
Alignment of carbon-fiber can be controlled during the 3D printing process
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
Subscribe To Our Newsletter & Stay Updated